AU2008210586B2 - Use of chromium histidinate for treatment of cardiometabolic disorders - Google Patents

Use of chromium histidinate for treatment of cardiometabolic disorders Download PDF

Info

Publication number: AU2008210586B2
Authority: AU; Australia
Prior art keywords: chromium; subject; composition; levels; disease
Prior art date: 2007-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2008210586A

Other languages

English (en)

Other versions

AU2008210586A1 (en

Inventor

Vijaya Juturu

James Komorowski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nutrition 21 LLC

Original Assignee

Nutrition 21 LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-31

Filing date

2008-01-29

Publication date

2013-07-04

2008-01-29 Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC

2008-08-07 Publication of AU2008210586A1 publication Critical patent/AU2008210586A1/en

2013-07-04 Application granted granted Critical

2013-07-04 Publication of AU2008210586B2 publication Critical patent/AU2008210586B2/en

Status Ceased legal-status Critical Current

2028-01-29 Anticipated expiration legal-status Critical

Links

XSSMKBYYGOUGFP-BBDGQJMTSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid chromium Chemical compound [Cr].OC(=O)[C@@H](N)CC1=CNC=N1.OC(=O)[C@@H](N)CC1=CNC=N1.OC(=O)[C@@H](N)CC1=CNC=N1 XSSMKBYYGOUGFP-BBDGQJMTSA-N 0.000 title claims abstract description 105
238000011282 treatment Methods 0.000 title abstract description 75
239000000203 mixture Substances 0.000 claims abstract description 233
239000011651 chromium Substances 0.000 claims abstract description 168
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 166
229910052804 chromium Inorganic materials 0.000 claims abstract description 166
238000000034 method Methods 0.000 claims abstract description 93
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 46
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 45
239000003814 drug Substances 0.000 claims description 71
229960002885 histidine Drugs 0.000 claims description 39
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 33
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 32
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 20
235000001968 nicotinic acid Nutrition 0.000 claims description 17
239000011664 nicotinic acid Substances 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 16
229960003512 nicotinic acid Drugs 0.000 claims description 16
229940081066 picolinic acid Drugs 0.000 claims description 15
239000002738 chelating agent Substances 0.000 claims description 14
235000021588 free fatty acids Nutrition 0.000 claims description 13
229960000890 hydrocortisone Drugs 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 6
238000007911 parenteral administration Methods 0.000 claims description 3
208000001145 Metabolic Syndrome Diseases 0.000 abstract description 52
230000002265 prevention Effects 0.000 abstract description 44
230000006872 improvement Effects 0.000 abstract description 8
235000012721 chromium Nutrition 0.000 description 152
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 142
208000001072 type 2 diabetes mellitus Diseases 0.000 description 109
206010022489 Insulin Resistance Diseases 0.000 description 104
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 101
150000001875 compounds Chemical class 0.000 description 87
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 85
229940107161 cholesterol Drugs 0.000 description 66
208000024172 Cardiovascular disease Diseases 0.000 description 58
206010012601 diabetes mellitus Diseases 0.000 description 57
235000012000 cholesterol Nutrition 0.000 description 56
210000004369 blood Anatomy 0.000 description 54
239000008280 blood Substances 0.000 description 54
102000004877 Insulin Human genes 0.000 description 51
108090001061 Insulin Proteins 0.000 description 51
229940079593 drug Drugs 0.000 description 50
229940125396 insulin Drugs 0.000 description 50
208000035475 disorder Diseases 0.000 description 49
108010010234 HDL Lipoproteins Proteins 0.000 description 45
102000015779 HDL Lipoproteins Human genes 0.000 description 45
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 40
241000700159 Rattus Species 0.000 description 40
239000008103 glucose Substances 0.000 description 39
201000010099 disease Diseases 0.000 description 35
208000008589 Obesity Diseases 0.000 description 34
235000020824 obesity Nutrition 0.000 description 34
208000032928 Dyslipidaemia Diseases 0.000 description 33
108010007622 LDL Lipoproteins Proteins 0.000 description 31
102000007330 LDL Lipoproteins Human genes 0.000 description 31
210000002966 serum Anatomy 0.000 description 30
150000002632 lipids Chemical class 0.000 description 29
230000009469 supplementation Effects 0.000 description 29
241000124008 Mammalia Species 0.000 description 27
150000001844 chromium Chemical class 0.000 description 27
206010020772 Hypertension Diseases 0.000 description 26
150000001413 amino acids Chemical class 0.000 description 25
229940024606 amino acid Drugs 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
102000004895 Lipoproteins Human genes 0.000 description 22
108090001030 Lipoproteins Proteins 0.000 description 22
-1 cholesterol lipid Chemical class 0.000 description 22
230000007423 decrease Effects 0.000 description 22
208000017169 kidney disease Diseases 0.000 description 22
108010062497 VLDL Lipoproteins Proteins 0.000 description 21
238000010521 absorption reaction Methods 0.000 description 21
230000000694 effects Effects 0.000 description 21
235000009200 high fat diet Nutrition 0.000 description 21
239000002245 particle Substances 0.000 description 21
206010028980 Neoplasm Diseases 0.000 description 20
210000000941 bile Anatomy 0.000 description 20
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 19
230000003247 decreasing effect Effects 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
208000017170 Lipid metabolism disease Diseases 0.000 description 17
230000001965 increasing effect Effects 0.000 description 17
235000002639 sodium chloride Nutrition 0.000 description 17
241000282414 Homo sapiens Species 0.000 description 16
235000005911 diet Nutrition 0.000 description 16
239000003925 fat Substances 0.000 description 16
235000019197 fats Nutrition 0.000 description 16
235000013305 food Nutrition 0.000 description 16
210000004185 liver Anatomy 0.000 description 16
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 16
208000024827 Alzheimer disease Diseases 0.000 description 15
201000001881 impotence Diseases 0.000 description 15
230000037356 lipid metabolism Effects 0.000 description 15
229940124597 therapeutic agent Drugs 0.000 description 15
201000001320 Atherosclerosis Diseases 0.000 description 14
208000029078 coronary artery disease Diseases 0.000 description 14
230000004153 glucose metabolism Effects 0.000 description 14
230000032258 transport Effects 0.000 description 14
150000003626 triacylglycerols Chemical class 0.000 description 14
235000013361 beverage Nutrition 0.000 description 13
230000036765 blood level Effects 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
230000002526 effect on cardiovascular system Effects 0.000 description 13
238000009472 formulation Methods 0.000 description 13
150000003839 salts Chemical class 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
108010046315 IDL Lipoproteins Proteins 0.000 description 12
201000011510 cancer Diseases 0.000 description 12
230000008030 elimination Effects 0.000 description 12
238000003379 elimination reaction Methods 0.000 description 12
208000018914 glucose metabolism disease Diseases 0.000 description 12
230000004054 inflammatory process Effects 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
108010059886 Apolipoprotein A-I Proteins 0.000 description 11
102000005666 Apolipoprotein A-I Human genes 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
206010003246 arthritis Diseases 0.000 description 11
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
230000037396 body weight Effects 0.000 description 11
239000002934 diuretic Substances 0.000 description 11
230000006870 function Effects 0.000 description 11
201000001421 hyperglycemia Diseases 0.000 description 11
229910052751 metal Inorganic materials 0.000 description 11
239000002184 metal Substances 0.000 description 11
208000010125 myocardial infarction Diseases 0.000 description 11
208000024891 symptom Diseases 0.000 description 11
206010060378 Hyperinsulinaemia Diseases 0.000 description 10
206010061218 Inflammation Diseases 0.000 description 10
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 10
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 10
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
230000007812 deficiency Effects 0.000 description 10
230000003451 hyperinsulinaemic effect Effects 0.000 description 10
201000008980 hyperinsulinism Diseases 0.000 description 10
150000002739 metals Chemical class 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
230000009467 reduction Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
229960001052 streptozocin Drugs 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
102100040214 Apolipoprotein(a) Human genes 0.000 description 9
241000282412 Homo Species 0.000 description 9
208000007536 Thrombosis Diseases 0.000 description 9
230000037213 diet Effects 0.000 description 9
230000001976 improved effect Effects 0.000 description 9
230000002757 inflammatory effect Effects 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
235000000891 standard diet Nutrition 0.000 description 9
208000011580 syndromic disease Diseases 0.000 description 9
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
102000013918 Apolipoproteins E Human genes 0.000 description 8
108010025628 Apolipoproteins E Proteins 0.000 description 8
108010074051 C-Reactive Protein Proteins 0.000 description 8
102100032752 C-reactive protein Human genes 0.000 description 8
206010012689 Diabetic retinopathy Diseases 0.000 description 8
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
235000014113 dietary fatty acids Nutrition 0.000 description 8
238000002651 drug therapy Methods 0.000 description 8
239000000194 fatty acid Substances 0.000 description 8
229930195729 fatty acid Natural products 0.000 description 8
150000004665 fatty acids Chemical class 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
208000002551 irritable bowel syndrome Diseases 0.000 description 8
239000003765 sweetening agent Substances 0.000 description 8
QJOSVOSTKBUREB-BBDGQJMTSA-K (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate;chromium(3+) Chemical compound [Cr+3].[O-]C(=O)[C@@H](N)CC1=CNC=N1.[O-]C(=O)[C@@H](N)CC1=CNC=N1.[O-]C(=O)[C@@H](N)CC1=CNC=N1 QJOSVOSTKBUREB-BBDGQJMTSA-K 0.000 description 7
102100040202 Apolipoprotein B-100 Human genes 0.000 description 7
101710115418 Apolipoprotein(a) Proteins 0.000 description 7
208000007342 Diabetic Nephropathies Diseases 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
208000022559 Inflammatory bowel disease Diseases 0.000 description 7
238000008214 LDL Cholesterol Methods 0.000 description 7
102000000853 LDL receptors Human genes 0.000 description 7
108010001831 LDL receptors Proteins 0.000 description 7
108010013563 Lipoprotein Lipase Proteins 0.000 description 7
206010033645 Pancreatitis Diseases 0.000 description 7
206010040047 Sepsis Diseases 0.000 description 7
208000006011 Stroke Diseases 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 7
QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 7
208000033679 diabetic kidney disease Diseases 0.000 description 7
230000000378 dietary effect Effects 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
239000000796 flavoring agent Substances 0.000 description 7
235000003599 food sweetener Nutrition 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 7
229960003105 metformin Drugs 0.000 description 7
230000004141 reverse cholesterol transport Effects 0.000 description 7
230000002441 reversible effect Effects 0.000 description 7
206010039073 rheumatoid arthritis Diseases 0.000 description 7
208000013223 septicemia Diseases 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
201000000596 systemic lupus erythematosus Diseases 0.000 description 7
239000003826 tablet Substances 0.000 description 7
102000018616 Apolipoproteins B Human genes 0.000 description 6
108010027006 Apolipoproteins B Proteins 0.000 description 6
206010003210 Arteriosclerosis Diseases 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
229910021555 Chromium Chloride Inorganic materials 0.000 description 6
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 6
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
229940100389 Sulfonylurea Drugs 0.000 description 6
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 6
230000005856 abnormality Effects 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
210000000577 adipose tissue Anatomy 0.000 description 6
239000000674 adrenergic antagonist Substances 0.000 description 6
239000002876 beta blocker Substances 0.000 description 6
229940097320 beta blocking agent Drugs 0.000 description 6
230000004087 circulation Effects 0.000 description 6
239000003086 colorant Substances 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
229940030606 diuretics Drugs 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
230000008694 endothelial dysfunction Effects 0.000 description 6
235000013355 food flavoring agent Nutrition 0.000 description 6
230000002440 hepatic effect Effects 0.000 description 6
238000002657 hormone replacement therapy Methods 0.000 description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
208000027866 inflammatory disease Diseases 0.000 description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
235000016709 nutrition Nutrition 0.000 description 6
229940127234 oral contraceptive Drugs 0.000 description 6
239000003539 oral contraceptive agent Substances 0.000 description 6
230000037361 pathway Effects 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
201000010065 polycystic ovary syndrome Diseases 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
108010008150 Apolipoprotein B-100 Proteins 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 5
208000017667 Chronic Disease Diseases 0.000 description 5
108010004103 Chylomicrons Proteins 0.000 description 5
206010009900 Colitis ulcerative Diseases 0.000 description 5
206010009944 Colon cancer Diseases 0.000 description 5
208000011231 Crohn disease Diseases 0.000 description 5
206010048554 Endothelial dysfunction Diseases 0.000 description 5
108010023302 HDL Cholesterol Proteins 0.000 description 5
208000035150 Hypercholesterolemia Diseases 0.000 description 5
102000043296 Lipoprotein lipases Human genes 0.000 description 5
208000018737 Parkinson disease Diseases 0.000 description 5
208000018262 Peripheral vascular disease Diseases 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
201000006704 Ulcerative Colitis Diseases 0.000 description 5
230000032683 aging Effects 0.000 description 5
239000007900 aqueous suspension Substances 0.000 description 5
208000011775 arteriosclerosis disease Diseases 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
229940046374 chromium picolinate Drugs 0.000 description 5
238000009142 chromium supplementation Methods 0.000 description 5
GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
239000003433 contraceptive agent Substances 0.000 description 5
230000001882 diuretic effect Effects 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
125000000896 monocarboxylic acid group Chemical group 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000035764 nutrition Effects 0.000 description 5
239000012053 oil suspension Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
201000008482 osteoarthritis Diseases 0.000 description 5
230000000291 postprandial effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
208000037803 restenosis Diseases 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
238000003860 storage Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000006188 syrup Substances 0.000 description 5
235000020357 syrup Nutrition 0.000 description 5
206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
206010006811 Bursitis Diseases 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 4
208000001640 Fibromyalgia Diseases 0.000 description 4
208000018522 Gastrointestinal disease Diseases 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
208000002705 Glucose Intolerance Diseases 0.000 description 4
201000005569 Gout Diseases 0.000 description 4
208000003456 Juvenile Arthritis Diseases 0.000 description 4
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
206010049287 Lipodystrophy acquired Diseases 0.000 description 4
206010027525 Microalbuminuria Diseases 0.000 description 4
208000000112 Myalgia Diseases 0.000 description 4
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 4
206010060862 Prostate cancer Diseases 0.000 description 4
208000000236 Prostatic Neoplasms Diseases 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
206010039710 Scleroderma Diseases 0.000 description 4
208000000491 Tendinopathy Diseases 0.000 description 4
206010043255 Tendonitis Diseases 0.000 description 4
229940123464 Thiazolidinedione Drugs 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
230000009471 action Effects 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
239000000556 agonist Substances 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
230000003078 antioxidant effect Effects 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
230000000923 atherogenic effect Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
239000002327 cardiovascular agent Substances 0.000 description 4
229940125692 cardiovascular agent Drugs 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
208000002849 chondrocalcinosis Diseases 0.000 description 4
HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 4
208000019069 chronic childhood arthritis Diseases 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
229940124558 contraceptive agent Drugs 0.000 description 4
235000015872 dietary supplement Nutrition 0.000 description 4
208000010643 digestive system disease Diseases 0.000 description 4
229940125753 fibrate Drugs 0.000 description 4
235000013376 functional food Nutrition 0.000 description 4
208000018685 gastrointestinal system disease Diseases 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000007943 implant Substances 0.000 description 4
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
208000006132 lipodystrophy Diseases 0.000 description 4
210000005229 liver cell Anatomy 0.000 description 4
244000144972 livestock Species 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
208000013465 muscle pain Diseases 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
230000007170 pathology Effects 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
208000005987 polymyositis Diseases 0.000 description 4
201000009104 prediabetes syndrome Diseases 0.000 description 4
230000008569 process Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
210000004872 soft tissue Anatomy 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
230000001502 supplementing effect Effects 0.000 description 4
201000004415 tendinitis Diseases 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
229940124549 vasodilator Drugs 0.000 description 4
239000003071 vasodilator agent Substances 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 3
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
239000005541 ACE inhibitor Substances 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 3
108010056301 Apolipoprotein C-III Proteins 0.000 description 3
102000030169 Apolipoprotein C-III Human genes 0.000 description 3
102100029470 Apolipoprotein E Human genes 0.000 description 3
101710095339 Apolipoprotein E Proteins 0.000 description 3
108010071619 Apolipoproteins Proteins 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 3
229940127291 Calcium channel antagonist Drugs 0.000 description 3
206010007559 Cardiac failure congestive Diseases 0.000 description 3
108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 3
102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
208000031226 Hyperlipidaemia Diseases 0.000 description 3
206010020880 Hypertrophy Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
108090001060 Lipase Proteins 0.000 description 3
208000034578 Multiple myelomas Diseases 0.000 description 3
229940126033 PPAR agonist Drugs 0.000 description 3
241000286209 Phasianidae Species 0.000 description 3
102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 3
108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
206010063837 Reperfusion injury Diseases 0.000 description 3
229930182558 Sterol Natural products 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
230000001594 aberrant effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
229940126317 angiotensin II receptor antagonist Drugs 0.000 description 3
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
239000002220 antihypertensive agent Substances 0.000 description 3
229940127088 antihypertensive drug Drugs 0.000 description 3
229960004676 antithrombotic agent Drugs 0.000 description 3
206010003119 arrhythmia Diseases 0.000 description 3
230000006793 arrhythmia Effects 0.000 description 3
230000003143 atherosclerotic effect Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
239000000480 calcium channel blocker Substances 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
230000008753 endothelial function Effects 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
230000004136 fatty acid synthesis Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
208000006575 hypertriglyceridemia Diseases 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
229960000905 indomethacin Drugs 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000007914 intraventricular administration Methods 0.000 description 3
230000003907 kidney function Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229940057995 liquid paraffin Drugs 0.000 description 3
210000004880 lymph fluid Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000004630 mental health Effects 0.000 description 3
230000007102 metabolic function Effects 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
239000003612 morphinomimetic agent Substances 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
208000031225 myocardial ischemia Diseases 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
102000014452 scavenger receptors Human genes 0.000 description 3
108010078070 scavenger receptors Proteins 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
150000003432 sterols Chemical class 0.000 description 3
235000003702 sterols Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
SLXTWXQUEZSSTJ-UHFFFAOYSA-N 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=2N=CC(=CC=2)C(O)=O)CC1 SLXTWXQUEZSSTJ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000004611 Abdominal Obesity Diseases 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
235000006491 Acacia senegal Nutrition 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
241000272525 Anas platyrhynchos Species 0.000 description 2
101710095342 Apolipoprotein B Proteins 0.000 description 2
108010024284 Apolipoprotein C-II Proteins 0.000 description 2
102000007592 Apolipoproteins Human genes 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
229940123208 Biguanide Drugs 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
208000007530 Essential hypertension Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
102000019267 Hepatic lipases Human genes 0.000 description 2
108050006747 Hepatic lipases Proteins 0.000 description 2
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
208000035180 MODY Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
241001494479 Pecora Species 0.000 description 2
241000009328 Perro Species 0.000 description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
208000008425 Protein deficiency Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
102000001494 Sterol O-Acyltransferase Human genes 0.000 description 2
108010054082 Sterol O-acyltransferase Proteins 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
241000287433 Turdus Species 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
108010069201 VLDL Cholesterol Proteins 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
210000000579 abdominal fat Anatomy 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
230000001466 anti-adreneric effect Effects 0.000 description 2
230000003531 anti-dysrhythmic effect Effects 0.000 description 2
239000000883 anti-obesity agent Substances 0.000 description 2
239000002111 antiemetic agent Substances 0.000 description 2
229940125683 antiemetic agent Drugs 0.000 description 2
108010073614 apolipoprotein A-IV Proteins 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
229960005370 atorvastatin Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
229920000080 bile acid sequestrant Polymers 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000037180 bone health Effects 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
229940097217 cardiac glycoside Drugs 0.000 description 2
239000002368 cardiac glycoside Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
229960005110 cerivastatin Drugs 0.000 description 2
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
150000001845 chromium compounds Chemical class 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
235000013325 dietary fiber Nutrition 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
229960000616 diflunisal Drugs 0.000 description 2
230000003028 elevating effect Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 2
229960000972 enoximone Drugs 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
235000020774 essential nutrients Nutrition 0.000 description 2
229940081345 estropipate Drugs 0.000 description 2
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 2
229960005293 etodolac Drugs 0.000 description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 2
230000029142 excretion Effects 0.000 description 2
201000001386 familial hypercholesterolemia Diseases 0.000 description 2
235000019625 fat content Nutrition 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229960002390 flurbiprofen Drugs 0.000 description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
229960003765 fluvastatin Drugs 0.000 description 2
235000020510 functional beverage Nutrition 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
208000004104 gestational diabetes Diseases 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
235000006486 human diet Nutrition 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004026 insulin derivative Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
108010022197 lipoprotein cholesterol Proteins 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
201000005857 malignant hypertension Diseases 0.000 description 2
238000007726 management method Methods 0.000 description 2
201000006950 maturity-onset diabetes of the young Diseases 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
208000025113 myeloid leukemia Diseases 0.000 description 2
229960004270 nabumetone Drugs 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
229940121367 non-opioid analgesics Drugs 0.000 description 2
150000005830 nonesterified fatty acids Chemical class 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
229960002702 piroxicam Drugs 0.000 description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
229960002965 pravastatin Drugs 0.000 description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000583 progesterone congener Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000003331 prothrombotic effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000004064 recycling Methods 0.000 description 2
230000036454 renin-angiotensin system Effects 0.000 description 2
208000004124 rheumatic heart disease Diseases 0.000 description 2
235000019204 saccharin Nutrition 0.000 description 2
229940081974 saccharin Drugs 0.000 description 2
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
229960002855 simvastatin Drugs 0.000 description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
229930002534 steroid glycoside Natural products 0.000 description 2
150000008143 steroidal glycosides Chemical class 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
229960000894 sulindac Drugs 0.000 description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000003451 thiazide diuretic agent Substances 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000006442 vascular tone Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
RNFRMTOEKIANFS-LJQANCHMSA-N (2S)-2-amino-3,3,3-triphenylpropanoic acid Chemical compound C1(=CC=CC=C1)C([C@H](N)C(=O)O)(C1=CC=CC=C1)C1=CC=CC=C1 RNFRMTOEKIANFS-LJQANCHMSA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
COTYIKUDNNMSDT-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 COTYIKUDNNMSDT-UHFFFAOYSA-N 0.000 description 1
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
VXMYWVMXSWJFCV-UHFFFAOYSA-N 3-(4-imidazol-1-ylphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=CC(=CC=2)N2C=NC=C2)=N1 VXMYWVMXSWJFCV-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
AFSHNJLKCYAWRX-UHFFFAOYSA-N 4-[(5-chloronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(Cl)=CC=CC2=CC=1CC1=NS(=O)ON1 AFSHNJLKCYAWRX-UHFFFAOYSA-N 0.000 description 1
GIYAQDDTCWHPPL-UHFFFAOYSA-N 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC GIYAQDDTCWHPPL-UHFFFAOYSA-N 0.000 description 1
BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
PNFZSRRRZNXSMF-UHFFFAOYSA-N 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid Chemical compound O=CC1=C(O)C(C)=NC(N=NC=2C(=CC(=CC=2)S(O)(=O)=O)S(O)(=O)=O)=C1COP(O)(O)=O PNFZSRRRZNXSMF-UHFFFAOYSA-N 0.000 description 1
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
YVQKIDLSVHRBGZ-UHFFFAOYSA-N 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1C(O)COC(C=C1)=CC=C1CC1SC(=O)NC1=O YVQKIDLSVHRBGZ-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101150037123 APOE gene Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
241000206501 Actaea <angiosperm> Species 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
241000272814 Anser sp. Species 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
108010087614 Apolipoprotein A-II Proteins 0.000 description 1
102000009081 Apolipoprotein A-II Human genes 0.000 description 1
102100037320 Apolipoprotein A-IV Human genes 0.000 description 1
108010012927 Apoprotein(a) Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000030767 Autoimmune encephalitis Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
108010087806 Carnosine Proteins 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
206010065941 Central obesity Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
229930195721 D-histidine Natural products 0.000 description 1
101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014612 Encephalitis viral Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
208000022461 Glomerular disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010018366 Glomerulonephritis acute Diseases 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
102000004366 Glucosidases Human genes 0.000 description 1
108010056771 Glucosidases Proteins 0.000 description 1
102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
206010018473 Glycosuria Diseases 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
208000005968 HIV-Associated Lipodystrophy Syndrome Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 1
102000030789 Histidine Ammonia-Lyase Human genes 0.000 description 1
108700006308 Histidine ammonia-lyases Proteins 0.000 description 1
108700028608 Histidinemia Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101001044367 Homo sapiens Immunoglobulin superfamily member 5 Proteins 0.000 description 1
208000010152 Huntington disease-like 3 Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
206010020586 Hypercalcaemic nephropathy Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010021024 Hypolipidaemia Diseases 0.000 description 1
102100022535 Immunoglobulin superfamily member 5 Human genes 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
229940122199 Insulin secretagogue Drugs 0.000 description 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
206010023379 Ketoacidosis Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
108010033266 Lipoprotein(a) Proteins 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
108010063312 Metalloproteins Proteins 0.000 description 1
102000010750 Metalloproteins Human genes 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010029148 Nephrolithiasis Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 1
208000010505 Nose Neoplasms Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
241000243985 Onchocerca volvulus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
101150098694 PDE5A gene Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
229940122985 Peptide agonist Drugs 0.000 description 1
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010051246 Photodermatosis Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
229940127315 Potassium Channel Openers Drugs 0.000 description 1
108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 description 1
208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
206010038470 Renal infarct Diseases 0.000 description 1
206010038540 Renal tubular necrosis Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
229940121908 Retinoid X receptor agonist Drugs 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010040954 Skin wrinkling Diseases 0.000 description 1
206010041277 Sodium retention Diseases 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
206010043515 Throat cancer Diseases 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000005434 White Coat Hypertension Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 1
UVAZQQHAVMNMHE-BBRMVZONSA-N [(3s,4s)-1,3-dimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-BBRMVZONSA-N 0.000 description 1
KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
229960001466 acetohexamide Drugs 0.000 description 1
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
206010000496 acne Diseases 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000037831 acute erythroleukemic leukemia Diseases 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 1
208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
229940126157 adrenergic receptor agonist Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229960001391 alfentanil Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229960001445 alitretinoin Drugs 0.000 description 1
229960003687 alizapride Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229960002512 anileridine Drugs 0.000 description 1
LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000037007 arousal Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
229950005951 azasetron Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004564 benzquinamide Drugs 0.000 description 1
229950000011 betaprodine Drugs 0.000 description 1
229960004324 betaxolol Drugs 0.000 description 1
CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
229960002938 bexarotene Drugs 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
230000003592 biomimetic effect Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
229960003065 bosentan Drugs 0.000 description 1
SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960001034 bromopride Drugs 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
229960001705 buclizine Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960004111 buformin Drugs 0.000 description 1
XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
229960004064 bumetanide Drugs 0.000 description 1
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
229940044199 carnosine Drugs 0.000 description 1
CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
229960001222 carteolol Drugs 0.000 description 1
LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006790 cellular biosynthetic process Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
229960001761 chlorpropamide Drugs 0.000 description 1
229960001523 chlortalidone Drugs 0.000 description 1
GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960000359 chromic chloride Drugs 0.000 description 1
229940060736 chromium polynicotinate Drugs 0.000 description 1
239000011636 chromium(III) chloride Substances 0.000 description 1
235000007831 chromium(III) chloride Nutrition 0.000 description 1
UUJXLQFXVJLMDM-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 UUJXLQFXVJLMDM-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229950009226 ciglitazone Drugs 0.000 description 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960001791 clebopride Drugs 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229960002577 colestipol hydrochloride Drugs 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
229940035811 conjugated estrogen Drugs 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
150000004696 coordination complex Chemical class 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
206010011005 corneal dystrophy Diseases 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
238000010580 coupled enzyme reaction Methods 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
229950002213 cyclazocine Drugs 0.000 description 1
229960003564 cyclizine Drugs 0.000 description 1
UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
229950006689 darglitazone Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000856 decreased creatinine clearance Toxicity 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960004597 dexfenfluramine Drugs 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
229960004042 diazoxide Drugs 0.000 description 1
229960004515 diclofenac potassium Drugs 0.000 description 1
KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
229960001193 diclofenac sodium Drugs 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
235000001434 dietary modification Nutrition 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960004993 dimenhydrinate Drugs 0.000 description 1
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
GGWBHVILAJZWKJ-UHFFFAOYSA-N dimethyl-[[5-[2-[[1-(methylamino)-2-nitroethenyl]amino]ethylsulfanylmethyl]furan-2-yl]methyl]azanium;chloride Chemical compound Cl.[O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-UHFFFAOYSA-N 0.000 description 1
OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
229960003520 diphenidol Drugs 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003413 dolasetron Drugs 0.000 description 1
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
229960001253 domperidone Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
CKFBRGLGTWAVLG-GOMYTPFNSA-N elcometrine Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 CKFBRGLGTWAVLG-GOMYTPFNSA-N 0.000 description 1
229950007611 elcometrine Drugs 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
229950002375 englitazone Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
229960000569 ethoheptazine Drugs 0.000 description 1
WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
229960002941 etonogestrel Drugs 0.000 description 1
CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
229950004155 etorphine Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
229960001582 fenfluramine Drugs 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
229960005341 fenoprofen calcium Drugs 0.000 description 1
VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
229960003240 floctafenine Drugs 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
229960001764 glibornuride Drugs 0.000 description 1
RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
229960000346 gliclazide Drugs 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
229960003468 gliquidone Drugs 0.000 description 1
229960003236 glisoxepide Drugs 0.000 description 1
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
231100000852 glomerular disease Toxicity 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
231100000853 glomerular lesion Toxicity 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229950005514 glycyclamide Drugs 0.000 description 1
RIGBPMDIGYBTBJ-UHFFFAOYSA-N glycyclamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 RIGBPMDIGYBTBJ-UHFFFAOYSA-N 0.000 description 1
229950008290 glyhexamide Drugs 0.000 description 1
NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 description 1
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
229960003727 granisetron Drugs 0.000 description 1
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
208000025750 heavy chain disease Diseases 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
201000002222 hemangioblastoma Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000001553 hepatotropic effect Effects 0.000 description 1
208000006599 histidinemia Diseases 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229960000930 hydroxyzine Drugs 0.000 description 1
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
208000029498 hypoalphalipoproteinemia Diseases 0.000 description 1
230000000871 hypocholesterolemic effect Effects 0.000 description 1
230000000396 hypokalemic effect Effects 0.000 description 1
208000009326 ileitis Diseases 0.000 description 1
229950000254 imazodan Drugs 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000036737 immune function Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
229940044513 implanon Drugs 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
229960004569 indapamide Drugs 0.000 description 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
229950009272 isomethadone Drugs 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
229960004384 ketorolac tromethamine Drugs 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229960001632 labetalol Drugs 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
229960003406 levorphanol Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
108010053156 lipid transfer protein Proteins 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
239000002171 loop diuretic Substances 0.000 description 1
208000020442 loss of weight Diseases 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229940072082 magnesium salicylate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
201000004641 malignant secondary hypertension Diseases 0.000 description 1
LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
229940013798 meclofenamate Drugs 0.000 description 1
229960001474 meclozine Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000009179 medical nutrition therapy Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
208000009242 medullary sponge kidney Diseases 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000001457 metallic cations Chemical class 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
XMQICEWOKPEQRG-UHFFFAOYSA-N methallatal Chemical compound CC(=C)CC1(CC)C(=O)NC(=S)NC1=O XMQICEWOKPEQRG-UHFFFAOYSA-N 0.000 description 1
229950010373 methallatal Drugs 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960002817 metolazone Drugs 0.000 description 1
AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 1
229960000767 metopimazine Drugs 0.000 description 1
NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 description 1
229950006080 metopon Drugs 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
229960001110 miglitol Drugs 0.000 description 1
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
229960003574 milrinone Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960003063 molgramostim Drugs 0.000 description 1
108010032806 molgramostim Proteins 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000003007 myelin sheath Anatomy 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
229960002967 nabilone Drugs 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
229960003940 naproxen sodium Drugs 0.000 description 1
CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
208000037830 nasal cancer Diseases 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
230000002988 nephrogenic effect Effects 0.000 description 1
201000002648 nephronophthisis Diseases 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960002497 nicorandil Drugs 0.000 description 1
LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 1
229960004190 nomegestrol acetate Drugs 0.000 description 1
229940053934 norethindrone Drugs 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
229950006134 normorphine Drugs 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000002417 nutraceutical Substances 0.000 description 1
235000021436 nutraceutical agent Nutrition 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
208000002042 onchocerciasis Diseases 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
229960005118 oxymorphone Drugs 0.000 description 1
229960000649 oxyphenbutazone Drugs 0.000 description 1
CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000016236 parenteral nutrition Nutrition 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
229960002035 penbutolol Drugs 0.000 description 1
KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000810 peripheral vasodilating agent Substances 0.000 description 1
229960002116 peripheral vasodilator Drugs 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
229960000897 phenazocine Drugs 0.000 description 1
229950008557 phenbutamide Drugs 0.000 description 1
AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
229960003562 phentermine Drugs 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000008845 photoaging Effects 0.000 description 1
SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
OSJJYEUEJRVVOD-UHFFFAOYSA-N pipamazine Chemical compound C1CC(C(=O)N)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 OSJJYEUEJRVVOD-UHFFFAOYSA-N 0.000 description 1
229950008580 pipamazine Drugs 0.000 description 1
235000002378 plant sterols Nutrition 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
239000004036 potassium channel stimulating agent Substances 0.000 description 1
229940097241 potassium-sparing diuretic Drugs 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000023341 pressure natriuresis Effects 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
229960003910 promethazine Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000001012 protector Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
AKMJJGSUTRBWGW-UHFFFAOYSA-N pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 AKMJJGSUTRBWGW-UHFFFAOYSA-N 0.000 description 1
YVVONORJTFWCED-UHFFFAOYSA-N pyridine-2-carboxylic acid pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.OC(=O)C1=CC=CC=N1 YVVONORJTFWCED-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
230000026313 regulation of carbohydrate metabolic process Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
229960003394 remifentanil Drugs 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
201000010384 renal tubular acidosis Diseases 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960000953 salsalate Drugs 0.000 description 1
229960002530 sargramostim Drugs 0.000 description 1
108010038379 sargramostim Proteins 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
230000000580 secretagogue effect Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000035946 sexual desire Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
208000027765 speech disease Diseases 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
239000007921 spray Substances 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
229960004739 sufentanil Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
XMFCOYRWYYXZMY-UHFFFAOYSA-N sulmazole Chemical compound COC1=CC(S(C)=O)=CC=C1C1=NC2=NC=CC=C2N1 XMFCOYRWYYXZMY-UHFFFAOYSA-N 0.000 description 1
229950006153 sulmazole Drugs 0.000 description 1
229960004940 sulpiride Drugs 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
201000010965 sweat gland carcinoma Diseases 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229960004869 thiethylperazine Drugs 0.000 description 1
XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
229960003397 thioproperazine Drugs 0.000 description 1
VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 1
230000035922 thirst Effects 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
229960002277 tolazamide Drugs 0.000 description 1
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
229960002044 tolmetin sodium Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
229960001288 triamterene Drugs 0.000 description 1
FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
229960004161 trimethobenzamide Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
229960003688 tropisetron Drugs 0.000 description 1
UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
201000002498 viral encephalitis Diseases 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000001993 wax Substances 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU2008210586A 2007-01-31 2008-01-29 Use of chromium histidinate for treatment of cardiometabolic disorders Ceased AU2008210586B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US88756107P	2007-01-31	2007-01-31
US60/887,561		2007-01-31
PCT/US2008/052352 WO2008094939A1 (en)	2007-01-31	2008-01-29	Use of chromium histidinate for treatment of cardiometabolic disorders

Publications (2)

Publication Number	Publication Date
AU2008210586A1 AU2008210586A1 (en)	2008-08-07
AU2008210586B2 true AU2008210586B2 (en)	2013-07-04

Family

ID=39674481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2008210586A Ceased AU2008210586B2 (en)	2007-01-31	2008-01-29	Use of chromium histidinate for treatment of cardiometabolic disorders

Country Status (6)

Country	Link
US (4)	US20100009015A1 (es)
EP (1)	EP2120930A4 (es)
AU (1)	AU2008210586B2 (es)
CA (3)	CA2931881C (es)
MX (1)	MX2009008135A (es)
WO (1)	WO2008094939A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008112706A1 (en)	2007-03-13	2008-09-18	Nutrition 21, Inc.	Methods and compositions for the sustained release of chromium
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2011002939A1 (en)	2009-07-01	2011-01-06	Nutrition 21, Inc.	Chromium complexes as enhancers of brain glucose transporters
EP4070801A1 (en)	2011-03-01	2022-10-12	Nutrition 21, LLC	Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US20130110531A1 (en) *	2011-10-29	2013-05-02	Kenneth O Russell	Method for reducing healthcare costs
GB2587289B (en) *	2015-06-23	2021-06-23	Jds Therapeutics Llc	Chromium Histidinate Complexes
MX2018009748A (es)	2016-02-11	2019-02-07	Nutrition 21 Llc	Composiciones que contienen cromo para mejorar la salud y el estado físico.
US20190183928A1 (en) *	2016-08-08	2019-06-20	Glucare Llc	Pharmaceutical compositions comprising chromium and carbohydrate blockers
EP3716962A1 (en)	2017-12-01	2020-10-07	INSERM - Institut National de la Santé et de la Recherche Médicale	Use of triethylenetetramine (teta) for the therapeutic induction of autophagy
WO2019238934A1 (en)	2018-06-15	2019-12-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of the apolipoprotein m for the treatment and diagnosis of insulin resistance
WO2020172262A1 (en) *	2019-02-19	2020-08-27	James Janine	Chromium composition and methods thereof
EP4309733A1 (en)	2022-07-22	2024-01-24	Institut National de la Santé et de la Recherche Médicale (INSERM)	Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020098247A1 (en) *	2000-11-02	2002-07-25	Komorowski James R.	Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
US6689383B1 (en) *	1999-10-08	2004-02-10	The United States Of America As Represented By The Secretary Of Agriculture	Chromium-histidine complexes as nutrient supplements

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0016496B1 (en) *	1979-03-19	1983-10-19	THE PROCTER & GAMBLE COMPANY	Chromium acetylacetonate as a dietary supplement and pharmaceutical agent
US4315927A (en) *	1980-08-08	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Dietary supplementation with essential metal picolinates
USRE33988E (en) *	1980-08-08	1992-07-07	The United States of America as repesented by the Secretary of Agriculture	Dietary supplementation with essential metal picolinates
US5194615A (en) *	1983-07-08	1993-03-16	The William Seroy Group	Synthetic GTF chromium nicotinate material and its preparation
US4954492A (en) *	1983-07-08	1990-09-04	The William Seroy Group	Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5087623A (en) *	1988-05-31	1992-02-11	Nitrition 21	Chromic picolinate treatment
US5175156A (en) *	1987-11-30	1992-12-29	Nutrition 21	Chromic picolinate treatment
US6140304A (en) *	1988-09-28	2000-10-31	Eicotech Corporation	Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
US5087624A (en) *	1989-03-21	1992-02-11	Nutrition 21	Chromic picolinate treatment
US5614553A (en) *	1990-07-06	1997-03-25	Albion Laboratories, Inc.	Composition and method for alleviating stress in warm-blooded animals
US5164384A (en) *	1991-06-19	1992-11-17	Metagenics, Inc.	Anabolic mineral formula
US5336672A (en) *	1992-07-21	1994-08-09	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Increasing egg production in poultry
SE9203753D0 (sv) *	1992-12-11	1992-12-11	Kabi Pharmacia Ab	Expression system for producing apolipoprotein ai-m
US5496827A (en) *	1994-07-15	1996-03-05	Patrick; Jay	Compositions for the transdermal delivery of nutrients
US6329361B1 (en) *	1995-05-12	2001-12-11	Nutrition 21	High-dose chromic picolinate treatment of type II diabetes
US5597585A (en) *	1995-12-26	1997-01-28	Williams; Andrew H.	Vitamin/mineral composition
US5635535A (en) *	1996-04-05	1997-06-03	Wagstaff; Robert K.	Method for increasing blood glucose levels
BR9811137A (pt) *	1997-08-08	2000-07-18	Nutrition 21	Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético
US5789401A (en) *	1997-08-08	1998-08-04	Nutrition 21	High-dose chromium/biotin treatment of type II diabetes
US6004925A (en) *	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) *	1997-09-29	2000-03-14	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6048846A (en) *	1998-02-26	2000-04-11	Cochran; Timothy M.	Compositions used in human treatment
US5948772A (en) *	1998-08-28	1999-09-07	Ambi Inc.	Chromium picolinate compositions and uses thereof
US6376549B1 (en) *	1998-09-17	2002-04-23	Akesis Pharmaceuticals, Inc.	Metforimin-containing compositions for the treatment of diabetes
DE60104450T2 (de) *	2000-09-21	2005-09-15	Nutrition 21, Inc.	Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
EP1397148B1 (en) *	2001-02-27	2006-09-20	Nutrition 21, Inc.	Chromium/biotin treatment of dyslipidemia
EP1496881A4 (en) *	2002-04-23	2007-04-04	Nutrition 21 Inc	CHROMIUM COMPOSITIONS AND METHOD FOR USE THEREOF FOR INHIBITING MEDICAMENT-RELATED INSULIN RESISTANCE
US7063865B2 (en) *	2002-05-10	2006-06-20	Jeremy Park Jones	Composition and method for substantially reducing the deleterious effects of alcohol on the body
US20040005368A1 (en) *	2002-07-01	2004-01-08	Morris Mann	Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US20050069593A1 (en) *	2003-09-29	2005-03-31	Life Time Fitness, Inc.	Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
US20060024383A1 (en) *	2004-07-27	2006-02-02	Roger Berlin	Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses
WO2008112706A1 (en) *	2007-03-13	2008-09-18	Nutrition 21, Inc.	Methods and compositions for the sustained release of chromium

2008
- 2008-01-29 AU AU2008210586A patent/AU2008210586B2/en not_active Ceased
- 2008-01-29 CA CA2931881A patent/CA2931881C/en active Active
- 2008-01-29 MX MX2009008135A patent/MX2009008135A/es active IP Right Grant
- 2008-01-29 CA CA3021932A patent/CA3021932C/en active Active
- 2008-01-29 WO PCT/US2008/052352 patent/WO2008094939A1/en not_active Ceased
- 2008-01-29 EP EP08714104A patent/EP2120930A4/en not_active Withdrawn
- 2008-01-29 CA CA2676977A patent/CA2676977C/en active Active
2009
- 2009-07-30 US US12/512,430 patent/US20100009015A1/en not_active Abandoned
2012
- 2012-09-14 US US13/620,464 patent/US20130101681A1/en not_active Abandoned
2015
- 2015-06-09 US US14/734,618 patent/US20150272991A1/en not_active Abandoned
2021
- 2021-04-06 US US17/224,009 patent/US20220023337A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6689383B1 (en) *	1999-10-08	2004-02-10	The United States Of America As Represented By The Secretary Of Agriculture	Chromium-histidine complexes as nutrient supplements
US20020098247A1 (en) *	2000-11-02	2002-07-25	Komorowski James R.	Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid

Also Published As

Publication number	Publication date
MX2009008135A (es)	2009-08-12
EP2120930A4 (en)	2012-12-05
CA2931881C (en)	2018-12-11
CA2676977A1 (en)	2008-08-07
US20220023337A1 (en)	2022-01-27
AU2008210586A1 (en)	2008-08-07
US20150272991A1 (en)	2015-10-01
US20100009015A1 (en)	2010-01-14
CA2931881A1 (en)	2008-08-07
EP2120930A1 (en)	2009-11-25
CA2676977C (en)	2016-10-04
WO2008094939A1 (en)	2008-08-07
CA3021932C (en)	2020-12-15
US20130101681A1 (en)	2013-04-25
CA3021932A1 (en)	2008-08-07

Publication	Publication Date	Title
US10245325B2 (en)	2019-04-02	Methods and compositions for the sustained release of chromium
US20220023337A1 (en)	2022-01-27	Use of chromium histidinate for treatment of cardiometabolic disorders
JP3699124B2 (ja)	2005-09-28	タイプｉｉ糖尿病のピコリン酸クロム高用量治療
EP1496881A2 (en)	2005-01-19	Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
EP2448412B1 (en)	2019-05-01	Chromium complexes as enhancers of brain glucose transporters
EP1400246B1 (en)	2006-11-02	Oral compositions for the treatment of obese, non-diabetic mammals, including humans
US8314080B2 (en)	2012-11-20	Method of treating type I diabetes

Legal Events

Date	Code	Title	Description
2013-10-31	FGA	Letters patent sealed or granted (standard patent)
2023-08-24	MK14	Patent ceased section 143(a) (annual fees not paid) or expired